NewAmsterdam Pharma Co. N.V.

NAMS

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001936258


None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $769.3M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Feb 18, 2026 265 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$18.96 2026-11-09; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 18, 2026

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol ("LDL-C") lowering therapy.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 54.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(6.9%)	(6.6%)		54.4	800	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 17.4						
Twelve-month failure probability	not computable	0.08%				
firm-wide XBRL shares cannot be assigned to one ticker class						
Altman Z double-prime	8.19	(0.35)		11.8	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	7.88x	2.95x		23.0	826	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 3						
Net share issuance, one year	not computable	2.5%				
firm-wide XBRL shares cannot be assigned to one ticker class						

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(35.9%)	(1.9%)	27
Distance from 52-week high	(54.2%)	(27.5%)	26
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.27	
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(0.61)	(0.19)	27

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$423.1M
Operating cash flow, four quarters	-$150.5M
Months of runway	33.7
Days since last periodic filing	6 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$30.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$203.8M	2025-12-31	2026-02-18	10-K	26-056029
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$147.8M	2025-12-31	2026-02-18	10-K	26-056029
3	assets	us-gaap:Assets	$769.3M	2025-12-31	2026-02-18	10-K	26-056029
4	assets	us-gaap:Assets	$864.6M	2024-12-31	2026-02-18	10-K	26-056029
5	current assets	us-gaap:AssetsCurrent	$675.7M	2025-12-31	2026-02-18	10-K	26-056029
6	current liabilities	us-gaap:LiabilitiesCurrent	$85.8M	2025-12-31	2026-02-18	10-K	26-056029
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$762.4M	2025-12-31	2026-02-18	10-K	26-056029
8	operating income	us-gaap:OperatingIncomeLoss	-$225.7M	2025-12-31	2026-02-18	10-K	26-056029
9	book equity	us-gaap:StockholdersEquity	$683.4M	2025-12-31	2026-02-18	10-K	26-056029
10	liabilities	us-gaap:Liabilities	$85.9M	2025-12-31	2026-02-18	10-K	26-056029
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$22.5M	2025-12-31	2026-02-18	10-K	26-056029
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$45.6M	2024-12-31	2026-02-18	10-K	26-056029
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.1M	2023-12-31	2026-02-18	10-K	26-056029
14	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$672,000	2024-12-31	2026-02-18	10-K	26-056029
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$113,000	2024-12-31	2026-02-18	10-K	26-056029
16	operating income	us-gaap:OperatingIncomeLoss	-$176.3M	2024-12-31	2026-02-18	10-K	26-056029
17	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$241.6M	2024-12-31	2026-02-18	10-K	26-056029
18	income tax	us-gaap:IncomeTaxExpenseBenefit	-$1,000	2024-12-31	2026-02-18	10-K	26-056029
19	current assets	us-gaap:AssetsCurrent	$863.4M	2024-12-31	2026-02-18	10-K	26-056029
20	current liabilities	us-gaap:LiabilitiesCurrent	$106.9M	2024-12-31	2026-02-18	10-K	26-056029
21	current assets	us-gaap:AssetsCurrent	$346.8M	2023-12-31	2025-02-26	10-K	25-027339
22	current liabilities	us-gaap:LiabilitiesCurrent	$49.9M	2023-12-31	2025-02-26	10-K	25-027339
23	assets	us-gaap:Assets	$347.1M	2023-12-31	2025-02-26	10-K	25-027339

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.